A Study of the Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects (0000-108)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01101763

108

2010_022

0000-108

Details and patient eligibility

About

This is a 2-part pilot study in healthy male subjects to evaluate plasma enrichment kinetics of [13C3,4]-cholesterol (Part I) and to assess the test-retest reproducibility (Part II) of Reverse Cholesterol Transport (RCT) measurements. The study will determine whether atom percent enrichment (% APE) at 18 hours can be extrapolated from the steady-state value and whether the mean difference in repeat Ra measurements is below is a prespecified level.

Enrollment: 20 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject is male 18 to 45 years of age at screening
• Subject has a stable weight (± 2 kg) for more then 6 weeks prior to screening

Exclusion criteria

• Subject has a history of ileal bypass, gastric bypass, or other significant condition associated with malabsorption
• Subject has an active or recent (<2 weeks) gastrointestinal condition (gastroenteritis, diarrhea, chronic constipation, irritable bowl syndrome, etc.) affecting bowel movements
• Subject has a known allergy to beans, peas, eggs or egg-derived products and/or soy or soy-derived products
• Subject has a history of plant sterol storage disease (sitosterolemia, cerebrotendinotic xanthomatosis) or a history of intolerance to plant sterols and/or plant sterol containing products
• Subject has a history of hepatic or gall bladder disease (including gallstones, cholecystectomy, etc.)
• Subject is currently taking psyllium, other fiber-based laxatives, phytosterol margarines, and/or over the counter (OTC) therapies that are known to affect serum lipids
• Subject has taken lipid-lowering agents within 6 weeks prior to screening
• Subject has previously been administered an intravenous infusion of [13C3,4]-cholesterol

Trial design

20 participants in 1 patient group

All Subjects

Description:

Healthy males